If it were on late-night cable, FDA’s expert panel meeting on attention deficit/hyperactivity disorder drugs might be called "Advisory Committees Gone Wild."
FDA convened its Drug Safety & Risk Management Advisory Committee on February 9 to discuss ways to study a potential increased risk of adverse cardiovascular outcomes among patients on ADHD...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?